This report describes the epidemiology, burden, and treatment of osteoporosis in the 27 countries of the European Union (EU27). Osteoporosis is characterized by reduced bone mass and disruption of bone architecture, increasing the risk of fragility fractures, which are the main clinical consequence. These fractures cause significant pain, disability, and even death, with substantial societal costs. The report aims to characterize the burden of osteoporosis in the EU27 in 2010 and beyond. The literature on fracture incidence and costs in the EU27 was reviewed, and a model was used to estimate the clinical and economic burden of osteoporotic fractures in 2010. It is estimated that 22 million women and 5.5 million men had osteoporosis, with 3.5 million new fragility fractures sustained, including 610,000 hip fractures, 520,000 vertebral fractures, 560,000 forearm fractures, and 1,800,000 other fractures. The economic burden of incident and prior fragility fractures was estimated at €37 billion, with 66% of this cost attributed to incident fractures, 29% to long-term care, and 5% to pharmacological prevention. The report also estimates that 1,180,000 quality-adjusted life years (QALYs) were lost in 2010 due to fractures. The costs are expected to increase by 25% by 2025. Most individuals with osteoporosis-related fractures or at high risk are untreated, and the number of patients on treatment is declining. The report highlights the high social and economic cost of osteoporosis, a substantial treatment gap, and projected increases in economic burden due to aging populations. Despite this, the use of pharmacological interventions to prevent fractures has decreased in recent years, suggesting a need for healthcare policy changes. The report covers the epidemiology, medical innovation, fracture burden, and treatment uptake of osteoporosis in the EU27, emphasizing the need for improved prevention and treatment strategies. It also discusses the global burden of osteoporosis, including the high incidence of fractures in Europe and the significant impact on quality of life and mortality. The report concludes that osteoporosis is a major non-communicable disease with increasing prevalence and burden, requiring urgent action to reduce its impact.This report describes the epidemiology, burden, and treatment of osteoporosis in the 27 countries of the European Union (EU27). Osteoporosis is characterized by reduced bone mass and disruption of bone architecture, increasing the risk of fragility fractures, which are the main clinical consequence. These fractures cause significant pain, disability, and even death, with substantial societal costs. The report aims to characterize the burden of osteoporosis in the EU27 in 2010 and beyond. The literature on fracture incidence and costs in the EU27 was reviewed, and a model was used to estimate the clinical and economic burden of osteoporotic fractures in 2010. It is estimated that 22 million women and 5.5 million men had osteoporosis, with 3.5 million new fragility fractures sustained, including 610,000 hip fractures, 520,000 vertebral fractures, 560,000 forearm fractures, and 1,800,000 other fractures. The economic burden of incident and prior fragility fractures was estimated at €37 billion, with 66% of this cost attributed to incident fractures, 29% to long-term care, and 5% to pharmacological prevention. The report also estimates that 1,180,000 quality-adjusted life years (QALYs) were lost in 2010 due to fractures. The costs are expected to increase by 25% by 2025. Most individuals with osteoporosis-related fractures or at high risk are untreated, and the number of patients on treatment is declining. The report highlights the high social and economic cost of osteoporosis, a substantial treatment gap, and projected increases in economic burden due to aging populations. Despite this, the use of pharmacological interventions to prevent fractures has decreased in recent years, suggesting a need for healthcare policy changes. The report covers the epidemiology, medical innovation, fracture burden, and treatment uptake of osteoporosis in the EU27, emphasizing the need for improved prevention and treatment strategies. It also discusses the global burden of osteoporosis, including the high incidence of fractures in Europe and the significant impact on quality of life and mortality. The report concludes that osteoporosis is a major non-communicable disease with increasing prevalence and burden, requiring urgent action to reduce its impact.